San Francisco Department of Public Health

DoxyPEP Demonstrates Significant Reduction in STIs in Real-World Setting

5 months ago

• A recent study published in JAMA Internal Medicine reveals that doxycycline post-exposure prophylaxis (doxyPEP) is associated with substantial declines in bacterial STIs. • The study, the largest of its kind, found a 79% reduction in chlamydia and an 80% reduction in syphilis among doxyPEP users in routine clinical care. • Gonorrhea rates saw a more modest 12% reduction, highlighting the need for continued STI testing and further research into prevention strategies. • These findings suggest that broader implementation of doxyPEP could significantly reduce STI transmission and improve sexual health, warranting vigilance for antimicrobial resistance.

Doxycycline Post-Exposure Prophylaxis Shows Promise in Reducing STIs in San Francisco

a year ago

• Doxycycline post-exposure prophylaxis (doxyPEP) has led to a significant reduction in sexually transmitted infections (STIs) among gay and bisexual men and transgender people in San Francisco. • Real-world data from San Francisco clinics and population-wide analyses align with clinical trial results, indicating doxyPEP's effectiveness in reducing chlamydia and syphilis. • While doxyPEP demonstrated a substantial impact on chlamydia and syphilis, its effect on gonorrhea was less pronounced, potentially due to drug resistance or adherence issues. • San Francisco's early adoption of doxyPEP guidelines has positioned it as a leader in STI prevention, with other cities and healthcare providers potentially following suit.

Doxy-PEP Shows Promise in STI Prevention, Balancing Benefits and Risks

2 years ago

• Doxycycline post-exposure prophylaxis (doxy-PEP) has demonstrated significant efficacy in reducing the incidence of gonorrhea, chlamydia, and syphilis among high-risk populations. • Studies show doxy-PEP is highly effective among MSM and TGW with a history of STIs, potentially increasing sexual pleasure and decreasing STI-related stigma. • Concerns remain regarding the long-term consequences of doxy-PEP, including the potential development of antibiotic resistance and disturbances to the microbiome. • Implementation of doxy-PEP requires careful consideration of benefits versus risks, with ongoing research needed to optimize its use and monitor its impact on antibiotic resistance.

Doxycycline as STI Prevention Shows High Efficacy with Limited Antibiotic Resistance

2 years ago

• A study on doxy-PEP, using doxycycline post-exposure prophylaxis, demonstrates high effectiveness in reducing bacterial STIs among men who have sex with men and transgender women. • The research found that doxy-PEP reduced gonorrhea, chlamydia, and syphilis infections by two-thirds each quarter over a year-long observation period. • While doxy-PEP was linked to a slight increase in tetracycline-resistant gonorrhea, the overall impact on antibiotic resistance appears minimal, necessitating further monitoring. • Doxy-PEP could potentially decrease the use of broad-spectrum antibiotics like ceftriaxone by mitigating recurrent STI treatments.